These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 24025726)

  • 1. Identification of potential synthetic lethal genes to p53 using a computational biology approach.
    Wang X; Simon R
    BMC Med Genomics; 2013 Sep; 6():30. PubMed ID: 24025726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignancy of Cancers and Synthetic Lethal Interactions Associated With Mutations of Cancer Driver Genes.
    Wang X; Zhang Y; Han ZG; He KY
    Medicine (Baltimore); 2016 Feb; 95(8):e2697. PubMed ID: 26937901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 mutations, expression and interaction networks in human cancers.
    Wang X; Sun Q
    Oncotarget; 2017 Jan; 8(1):624-643. PubMed ID: 27880943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ranking novel cancer driving synthetic lethal gene pairs using TCGA data.
    Ye H; Zhang X; Chen Y; Liu Q; Wei J
    Oncotarget; 2016 Aug; 7(34):55352-55367. PubMed ID: 27438146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting mutant p53 for cancer therapy: direct and indirect strategies.
    Hu J; Cao J; Topatana W; Juengpanich S; Li S; Zhang B; Shen J; Cai L; Cai X; Chen M
    J Hematol Oncol; 2021 Sep; 14(1):157. PubMed ID: 34583722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated genomic and pharmacological approaches to identify synthetic lethal genes as cancer therapeutic targets.
    Mizuarai S; Irie H; Schmatz DM; Kotani H
    Curr Mol Med; 2008 Dec; 8(8):774-83. PubMed ID: 19075675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Synthetic lethal genes to mutant p53].
    Liu TY; Guo HQ; Zhu MY; Huang YZ; Jia ST; Luo Y; Zhang JH
    Yi Chuan; 2015 Apr; 37(4):321-326. PubMed ID: 25881697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic lethal kinases in Ras/p53 mutant squamous cell carcinoma.
    Moser R; Gurley KE; Nikolova O; Qin G; Joshi R; Mendez E; Shmulevich I; Ashley A; Grandori C; Kemp CJ
    Oncogene; 2022 Jun; 41(24):3355-3369. PubMed ID: 35538224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-omic measurement of mutually exclusive loss-of-function enriches for candidate synthetic lethal gene pairs.
    Wappett M; Dulak A; Yang ZR; Al-Watban A; Bradford JR; Dry JR
    BMC Genomics; 2016 Jan; 17():65. PubMed ID: 26781748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic sickness or lethality points at candidate combination therapy targets in glioblastoma.
    Szczurek E; Misra N; Vingron M
    Int J Cancer; 2013 Nov; 133(9):2123-32. PubMed ID: 23629686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-Throughput RNA Interference Screen Targeting Synthetic-Lethal Gain-of-Function of Oncogenic Mutant TP53 in Triple-Negative Breast Cancer.
    Rokudai S
    Methods Mol Biol; 2020; 2108():297-303. PubMed ID: 31939190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High throughput RNAi screening identifies ID1 as a synthetic sick/lethal gene interacting with the common TP53 mutation R175H.
    Imai H; Kato S; Sakamoto Y; Kakudo Y; Shimodaira H; Ishioka C
    Oncol Rep; 2014 Mar; 31(3):1043-50. PubMed ID: 24378760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes.
    Liu C; Zhao J; Lu W; Dai Y; Hockings J; Zhou Y; Nussinov R; Eng C; Cheng F
    PLoS Comput Biol; 2020 Feb; 16(2):e1007701. PubMed ID: 32101536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer.
    Tang YC; Ho SC; Tan E; Ng AWT; McPherson JR; Goh GYL; Teh BT; Bard F; Rozen SG
    Breast Cancer Res; 2018 Mar; 20(1):22. PubMed ID: 29566768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
    Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
    Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome.
    Tiedemann RE; Zhu YX; Schmidt J; Shi CX; Sereduk C; Yin H; Mousses S; Stewart AK
    Cancer Res; 2012 Feb; 72(3):757-68. PubMed ID: 22147262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer in silico drug discovery: a systems biology tool for identifying candidate drugs to target specific molecular tumor subtypes.
    San Lucas FA; Fowler J; Chang K; Kopetz S; Vilar E; Scheet P
    Mol Cancer Ther; 2014 Dec; 13(12):3230-40. PubMed ID: 25349306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.
    O'Connor PM; Jackman J; Bae I; Myers TG; Fan S; Mutoh M; Scudiero DA; Monks A; Sausville EA; Weinstein JN; Friend S; Fornace AJ; Kohn KW
    Cancer Res; 1997 Oct; 57(19):4285-300. PubMed ID: 9331090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human synthetic lethal inference as potential anti-cancer target gene detection.
    Conde-Pueyo N; Munteanu A; Solé RV; Rodríguez-Caso C
    BMC Syst Biol; 2009 Dec; 3():116. PubMed ID: 20015360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation.
    Avery-Kiejda KA; Bowden NA; Croft AJ; Scurr LL; Kairupan CF; Ashton KA; Talseth-Palmer BA; Rizos H; Zhang XD; Scott RJ; Hersey P
    BMC Cancer; 2011 May; 11():203. PubMed ID: 21615965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.